|
SDHB expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.32989999410438E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.98759999570086E-08 |
| Normal-vs-Stage2 |
6.483600E-01 |
| Normal-vs-Stage3 |
1.12590003986668E-09 |
| Normal-vs-Stage4 |
5.57719999960682E-07 |
| Stage1-vs-Stage2 |
5.824100E-02 |
| Stage1-vs-Stage3 |
1.401000E-01 |
| Stage1-vs-Stage4 |
1.113170E-01 |
| Stage2-vs-Stage3 |
1.489610E-02 |
| Stage2-vs-Stage4 |
1.160100E-02 |
| Stage3-vs-Stage4 |
6.305800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.43759465337712E-11 |
| Normal-vs-AfricanAmerican |
1.904180E-02 |
| Normal-vs-Asian |
6.04330000000264E-05 |
| Caucasian-vs-AfricanAmerican |
2.326400E-01 |
| Caucasian-vs-Asian |
6.330600E-01 |
| AfricanAmerican-vs-Asian |
4.690400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.54229997848677E-09 |
| Normal-vs-Female |
9.35130000101481E-08 |
| Male-vs-Female |
1.267370E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.49739999955045E-07 |
| Normal-vs-Age(41-60Yrs) |
1.48569999636194E-08 |
| Normal-vs-Age(61-80Yrs) |
2.884200E-03 |
| Normal-vs-Age(81-100Yrs) |
1.936960E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.652800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.330800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.347600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.978000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.499400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.409000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.891600E-01 |
| Classical-VS-Follicular |
5.816700E-04 |
| Classical-VS-Other |
6.068600E-01 |
| Classical-VS-Normal |
9.81970060820458E-12 |
| Tall-VS-Follicular |
1.380810E-03 |
| Tall-VS-Other |
7.419200E-01 |
| Tall-VS-Normal |
1.33559999948574E-07 |
| Follicular-VS-Other |
1.780970E-01 |
| Follicular-VS-Normal |
5.089400E-01 |
| Other-VS-Normal |
5.566100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.63230000005399E-06 |
| Normal-vs-N1 |
5.16708897890794E-12 |
| N0-vs-N1 |
1.001120E-04 |
|
|
